ZURA

Zura Bio Limited

3.46 USD
+0.04 (+1.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Zura Bio Limited stock is down -38.65% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 June’s closed higher than May. 100% of analysts rate it a buy.

About Zura Bio Limited

Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and Torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.

  • Cantor Fitzgerald
    Mon Jun 17, 09:27
    buy
    confirm
  • Cantor Fitzgerald
    Wed Jun 12, 07:42
    buy
    initial